Analyst Consensus ?
ConsensusBuy23 ratings
Bullish1460.9%
Neutral626.1%
Bearish313.0%
Roper Technologies, Inc. · ROP · FY2024 Q4 · Calendar Q1 2025
Roper emphasizes cash generation, software bookings and M&A capacity
The supplied analysis supports a constructive but execution-dependent view: strong cash generation, high-teens enterprise software bookings, SaaS conversion, GenAI initiatives and substantial M&A capacity provide potential support for continued growth. The case is tempered by acquisition integration, macro exposure, AI competition, policy uncertainty and the absence of reported-versus-consensus results in the supplied facts.
Reported Before market openNASDAQTechnology
$36.74B market cap
80quality score
Earnings scorecard
Reported versus consensus
Reported EPS
—
Consensus $4.73
EPS surprise
—
Reported versus consensus
Reported revenue
—
Consensus $1.84B
Revenue surprise
—
Reported versus consensus
Market reaction
prior-close to event-session close
Stock move
+5.1%
Event window
SPY move
+0.5%
Same window
Abnormal move
+4.5%
Stock minus SPY
Volume
1.8×
Versus trailing sessions
Subsequent drift
+2.4%
Up to 20 sessions
ROPSPY benchmark
Ask FN2 about ROP FY2024 Q4
Transcript, numbers and history already loaded
What drove ROP's +5.1% move after FY2024 Q4 earnings?What changed in ROP's guidance and outlook in FY2024 Q4?Give me the bull and bear case for ROP after FY2024 Q4 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Compared with the prior-quarter analysis, the company’s acquisition capacity increased to more than $5 billion, Procare and Transact Campus became central to the growth and integration agenda, and GenAI deployment broadened across the portfolio. Guidance sentiment moved from raised in the prior analysis to maintained in the current analysis, while the current analysis added concerns about AI monetization, DAT pricing and GovCon policy.
Guidance delta
Maintained. The supplied analysis says 2025 guidance targets more than 10% total revenue growth, 6–7% organic growth, and adjusted EPS of $19.75–$20.
Key takeaways
- Management described free cash flow growth and a 32% cash-flow margin as evidence of continued cash compounding.
- Growth was described as evenly split between organic expansion and acquisitions, with Procare and Transact Campus highlighted.
- The company cited more than $5 billion of acquisition capacity and high-teens enterprise software bookings growth.
- GenAI rollout, SaaS conversion and recurring-revenue expansion remain central operating themes.
- The supplied analysis does not include actual EPS or revenue, so no reported beat or miss is stated.
Management priorities
- Deploy capital toward additional vertical-market software acquisitions.
- Integrate Transact Campus and Procare and pursue the planned cost synergies.
- Expand GenAI capabilities across Deltek, Aderant, DAT, ConstructConnect, Vertafore and other businesses.
- Accelerate SaaS migration of on-premise maintenance contracts.
- Continue talent development and leadership succession across portfolio companies.
Follow ROP with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$364.09Previous close
$355Low
$513.54Average
$665High
Latest persisted target per named analyst; persisted previous close from FN2's market snapshot as of Oct 12, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| RBC Capital | Sector Perform | Sector Perform | Maintain | Aug 18, 2026 |
| Argus Research | Buy | Hold | Upgrade | Aug 6, 2026 |
| JP Morgan | Underweight | Underweight | Maintain | Jul 29, 2026 |
| Piper Sandler | Overweight | Overweight | Maintain | Jul 24, 2026 |
| Barclays | Underweight | Underweight | Maintain | Apr 24, 2026 |
| Baird | Outperform | Outperform | Maintain | Apr 24, 2026 |
| Goldman Sachs | Neutral | Neutral | Maintain | Jan 29, 2026 |
| Truist Securities | Buy | Buy | Maintain | Jan 28, 2026 |
| Stifel | Hold | Buy | Downgrade | Jan 28, 2026 |
| Oppenheimer | Perform | Outperform | Downgrade | Jan 28, 2026 |
| Mizuho | Underperform | Underperform | Maintain | Jan 28, 2026 |
| Citigroup | Buy | Buy | Maintain | Jan 28, 2026 |
| Jefferies | Buy | Buy | Maintain | Jan 5, 2026 |
| TD Cowen | Buy | Buy | Maintain | Oct 24, 2025 |
| Raymond James | Strong Buy | Strong Buy | Maintain | Oct 24, 2025 |
| Wolfe Research | Peer Perform | Outperform | Downgrade | Jun 13, 2024 |
| Wells Fargo | Overweight | Overweight | Maintain | Jan 22, 2024 |
| Bernstein | Outperform | Market Perform | Upgrade | May 2, 2023 |
| Cowen & Co. | Outperform | Outperform | Maintain | Jul 26, 2022 |
| Stephens & Co. | Overweight | Overweight | Maintain | Apr 30, 2019 |
| Argus | Buy | Buy | Maintain | Aug 2, 2018 |
| Canaccord Genuity | Hold | Hold | Maintain | Feb 5, 2018 |
| Stifel Nicolaus | Buy | Buy | Maintain | Feb 2, 2016 |
Named analyst price targets
Upside is calculated against the persisted previous close $364.09. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Argus Research | Analyst unavailable | $450 | $394.53 | +23.6% | Aug 6, 2026 |
| RBC Capital | Deane Dray | $417 | $370.27 | +14.5% | Jul 24, 2026 |
| Robert W. Baird | Analyst unavailable | $480 | $355.12 | +31.8% | Jul 24, 2026 |
| Piper Sandler | Clarke Jeffries | $526 | $355.12 | +44.5% | Jul 24, 2026 |
| Mizuho Securities | Analyst unavailable | $355 | $362.84 | -2.5% | Jul 21, 2026 |
| BMO Capital | Daniel Jester | $393 | $355.94 | +7.9% | Jul 10, 2026 |
| RBC Capital | Analyst unavailable | $407 | $363.76 | +11.8% | Apr 24, 2026 |
| Robert W. Baird | Analyst unavailable | $470 | $363.76 | +29.1% | Apr 24, 2026 |
| Piper Sandler | Analyst unavailable | $540 | $363.76 | +48.3% | Apr 24, 2026 |
| Barclays | Analyst unavailable | $373 | $363.76 | +2.4% | Apr 24, 2026 |
| Goldman Sachs | Analyst unavailable | $440 | $360.37 | +20.8% | Jan 29, 2026 |
| RBC Capital | Analyst unavailable | $398 | $360.66 | +9.3% | Jan 28, 2026 |
| Mizuho Securities | Analyst unavailable | $365 | $360.98 | +0.2% | Jan 28, 2026 |
| Robert W. Baird | Analyst unavailable | $550 | $358.34 | +51.1% | Jan 28, 2026 |
| Jefferies | Analyst unavailable | $500 | $369.27 | +37.3% | Jan 28, 2026 |
| Barclays | Analyst unavailable | $409 | $369.27 | +12.3% | Jan 28, 2026 |
| Stifel Nicolaus | Analyst unavailable | $385 | $369.27 | +5.7% | Jan 27, 2026 |
| Truist Financial | Terry Tillman | $550 | $369.27 | +51.1% | Jan 27, 2026 |
| Melius Research | Scott Davis | $479 | $355.89 | +31.6% | Jan 27, 2026 |
| Oppenheimer | Analyst unavailable | $525 | $407.48 | +44.2% | Jan 23, 2026 |
| Piper Sandler | Clarke Jeffries | $530 | $432.39 | +45.6% | Jan 13, 2026 |
| Jefferies | Analyst unavailable | $600 | $430.77 | +64.8% | Jan 5, 2026 |
| Mizuho Securities | Analyst unavailable | $419 | $434.54 | +15.1% | Jan 5, 2026 |
| Barclays | Analyst unavailable | $475 | $445.89 | +30.5% | Dec 4, 2025 |
| Piper Sandler | Clarke Jeffries | $600 | $444.78 | +64.8% | Nov 19, 2025 |
| Barclays | Analyst unavailable | $506 | $470.18 | +39.0% | Oct 27, 2025 |
| RBC Capital | Analyst unavailable | $539 | $478.8 | +48.0% | Oct 27, 2025 |
| Truist Financial | Analyst unavailable | $650 | $479.85 | +78.5% | Oct 24, 2025 |
| Stifel Nicolaus | Analyst unavailable | $550 | $479.96 | +51.1% | Oct 24, 2025 |
| RBC Capital | Deane Dray | $644 | $479.96 | +76.9% | Oct 24, 2025 |
| Robert W. Baird | Analyst unavailable | $592 | $479.96 | +62.6% | Oct 24, 2025 |
| Raymond James | Brian Gesuale | $575 | $479.51 | +57.9% | Oct 24, 2025 |
| Jefferies | Analyst unavailable | $650 | $479.96 | +78.5% | Oct 23, 2025 |
| Oppenheimer | Ken Wong | $570 | $479.96 | +56.6% | Oct 23, 2025 |
| Mizuho Securities | Brett Linzey | $510 | $500.08 | +40.1% | Oct 17, 2025 |
| Barclays | Julian Mitchell | $550 | $498.69 | +51.1% | Oct 1, 2025 |
| Mizuho Securities | Brett Linzey | $600 | $582.88 | +64.8% | May 16, 2025 |
| Oppenheimer | Christopher Glynn | $640 | $557.7 | +75.8% | Apr 28, 2025 |
| Stifel Nicolaus | Analyst unavailable | $685 | $582.71 | +88.1% | Mar 26, 2025 |
| Robert W. Baird | Joe Vruwink | $665 | $575.65 | +82.6% | Jan 31, 2025 |
| Truist Financial | Terry Tillman | $665 | $542.94 | +82.6% | Oct 24, 2024 |
| Robert W. Baird | Richard Eastman | $652 | $542.94 | +79.1% | Oct 24, 2024 |
| RBC Capital | Deane Dray | $666 | $542.94 | +82.9% | Oct 24, 2024 |
| Robert W. Baird | Joe Vruwink | $635 | $531.97 | +74.4% | Jul 25, 2024 |
| Barclays | Julian Mitchell | $625 | $550.47 | +71.7% | Jul 10, 2024 |
| Argus Research | John Eade | $575 | $511.46 | +57.9% | Apr 30, 2024 |
| Wolfe Research | Brad Hewitt | $625 | $543.01 | +71.7% | Apr 8, 2024 |
| Oppenheimer | Christopher Glynn | $650 | $556.38 | +78.5% | Mar 22, 2024 |
| Goldman Sachs | Analyst unavailable | $468 | $429.25 | +28.5% | Dec 15, 2022 |
| RBC Capital | Analyst unavailable | $565 | $472.01 | +55.2% | Apr 27, 2022 |
| Cowen & Co. | Joseph C Giordano | $520 | $487.88 | +42.8% | Jul 26, 2021 |
| Oppenheimer | Christopher Glynn | $560 | $494.71 | +53.8% | Jul 23, 2021 |
Track every rating change on ROP the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationRoper Technologies, Inc., established in 1981 and based in Sarasota, Florida (formerly known as Roper Industries, Inc. until 2015), operates as a diversified technology company. It specializes in developing and delivering advanced software solutions alongside highly engineered products for a wide range of industries. Its extensive software portfolio includes enterprise and financial management systems, cloud-based analytics for sectors like insurance and healthcare, campus and supply chain management tools, and specialized applications for areas such as foodservice, visual effects, and data collaboration. Complementing this, Roper designs and manufactures a diverse array of engineered products, encompassing precision testing instruments for materials like rubber and plastic, medical devices (such as ultrasound accessories), flow and control components (including valves, pumps, and meters), automated dispensing and monitoring equipment (like leak detection and vibration monitoring systems), and various sensors for industrial and utility applications.
Historical context
All ROP earningsTechnology peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| ACN Accenture plc | FY2026 Q4 · Calendar Q4 2026 | +3.5% | +15.8% | Accenture: AI demand supports strong Q4, while pricing and geopolitics remain risks |
| JBL Jabil Inc. | FY2026 Q4 · Calendar Q3 2026 | +8.1% | -10.0% | Jabil enters FY2027 with AI-led growth and capacity risks |
| MU Micron Technology, Inc. | FY2026 Q4 · Calendar Q3 2026 | +5.4% | +0.0% | Micron: Strong AI Memory Demand, Higher Capex, and HBM4E Ahead |
| SNX TD Synnex Corp | FY2026 Q3 · Calendar Q3 2026 | +20.9% | -9.9% | TD SYNNEX: AI-led growth accelerates, but mix and cash flow matter |
| ADBE Adobe Inc. | FY2026 Q3 · Calendar Q3 2026 | +0.8% | +1.4% | Adobe raises FY26 outlook as AI strategy broadens |
| ORCL Oracle Corporation | FY2027 Q1 · Calendar Q3 2026 | +10.3% | -1.7% | Oracle raises FY27 outlook as AI demand accelerates cloud growth |
Latest beats and misses
Who reports nextBeat on EPS
Get the ROP recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2025-01-16T00:01:26.053560+00:00
- Polygon adjusted daily market bars · 2026-10-12T07:30:41.767942+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-12T07:30:41.765164+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-12. For educational purposes only; not investment advice.